These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 24859492)

  • 21. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.
    Piedra PA; Gaglani MJ; Riggs M; Herschler G; Fewlass C; Watts M; Kozinetz C; Hessel C; Glezen WP
    Pediatrics; 2005 Sep; 116(3):e397-407. PubMed ID: 16140685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2-8 Years in the U.S.
    Smith KJ; Raviotta JM; DePasse JV; Brown ST; Shim E; Patricia Nowalk M; Zimmerman RK
    Am J Prev Med; 2016 May; 50(5):600-608. PubMed ID: 26868283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of intranasal live attenuated influenza vaccine against all-cause acute otitis media in children.
    Heikkinen T; Block SL; Toback SL; Wu X; Ambrose CS
    Pediatr Infect Dis J; 2013 Jun; 32(6):669-74. PubMed ID: 23271441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of childhood rotavirus vaccination in Germany.
    Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O
    Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness and Health Impacts of Different Influenza Vaccination Strategies for Children in China.
    Gong Y; Yao X; Peng J; Ma Y; Fang Y; Yan K; Jiang M
    Am J Prev Med; 2023 Jul; 65(1):155-164. PubMed ID: 37037733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of live-attenuated influenza vaccination among school-age children.
    Wenzel NS; Atkins KE; van Leeuwen E; Halloran ME; Baguelin M
    Vaccine; 2021 Jan; 39(2):447-456. PubMed ID: 33280855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years.
    Prosser LA; Meltzer MI; Fiore A; Epperson S; Bridges CB; Hinrichsen V; Lieu TA
    Arch Pediatr Adolesc Med; 2011 Feb; 165(2):112-8. PubMed ID: 20921341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.
    Kuhlmann A; von der Schulenburg JG
    Eur J Health Econ; 2017 Apr; 18(3):273-292. PubMed ID: 26905404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine.
    Nichol KL; Mallon KP; Mendelman PM
    Vaccine; 2003 May; 21(17-18):2207-17. PubMed ID: 12706712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.
    Brydak L; Roiz J; Faivre P; Reygrobellet C
    Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.
    Piedra PA; Gaglani MJ; Kozinetz CA; Herschler GB; Fewlass C; Harvey D; Zimmerman N; Glezen WP
    Pediatrics; 2007 Sep; 120(3):e553-64. PubMed ID: 17698577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial.
    Nichol KL; Mendelman PM; Mallon KP; Jackson LA; Gorse GJ; Belshe RB; Glezen WP; Wittes J
    JAMA; 1999 Jul; 282(2):137-44. PubMed ID: 10411194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential cost savings attributable to influenza vaccination of school-aged children.
    White T; Lavoie S; Nettleman MD
    Pediatrics; 1999 Jun; 103(6):e73. PubMed ID: 10353970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economics of influenza vaccine administration timing for children.
    Lee BY; Tai JH; Bailey RR; Smith KJ; Nowalk AJ
    Am J Manag Care; 2010 Mar; 16(3):e75-e85. PubMed ID: 20205492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes.
    de Boer PT; Backer JA; van Hoek AJ; Wallinga J
    BMC Med; 2020 Jan; 18(1):11. PubMed ID: 31931789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.
    Clements KM; Chancellor J; Nichol K; DeLong K; Thompson D
    Value Health; 2011; 14(6):800-11. PubMed ID: 21914499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G; Gregg M; Poulsen Nautrup B
    J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of Strategies for Offering Influenza Vaccine in the Pediatric Emergency Department.
    Hart RJ; Stevenson MD; Smith MJ; LaJoie AS; Cross K
    JAMA Pediatr; 2018 Jan; 172(1):e173879. PubMed ID: 29114729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) pilot study: a cluster randomized trial.
    Kwong JC; Pereira JA; Quach S; Pellizzari R; Dusome E; Russell ML; Hamid JS; Feinberg Y; Winter AL; Gubbay JB; Sirtonski B; Moher D; Sider D; Finkelstein M; Loeb M;
    Vaccine; 2015 Jan; 33(4):535-41. PubMed ID: 25488331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.